a r t I C l e S Dyslipidemia, obesity, hypertension and impaired glucose meta bolism are hallmarks of the metabolic syndrome 1 , but limited information about the common molecular underpinnings of this syndrome has hampered efforts to treat it in its entirety. Efforts to find pharmacological therapeutics have resulted in an increas ingly sophisticated model of molecular energy balance regulation.
a r t I C l e S Dyslipidemia, obesity, hypertension and impaired glucose meta bolism are hallmarks of the metabolic syndrome 1 , but limited information about the common molecular underpinnings of this syndrome has hampered efforts to treat it in its entirety. Efforts to find pharmacological therapeutics have resulted in an increas ingly sophisticated model of molecular energy balance regulation.
As an important part of that model, the gut hormone ghrelin is believed to inform the brain about energy availability and has been shown to increase adiposity, raise blood pressure and promote hyperglycemia 2 . The overwhelming majority of ghrelin's effects on metabolism are mediated via CNS circuits, with the hypotha lamic melanocortin system arguably being its most important direct target 3 . In turn, the melanocortin system is an essential and potent regulator of body adiposity, glucose metabolism and blood pressure 4 . Furthermore, mutations of melanocortin receptors are strongly correlated with human obesity 5 and alterations in choles terol transport are a common occurrence in obesity and the meta bolic syndrome 6 . We hypothesized that a gutbrain axis integrates all of the primary physiological components known to be affected in the metabolic syndrome, that, in addition to regulating glucose homeostasis, blood pressure, food intake and body weight, it also likely controls cholesterol metabolism. We found that a gutbrain axis including ghrelin, glucagonlike peptide 1 (GLP1) and the central melanocortin system directly regulates the hepatic synthesis and reuptake of cholesterol.
RESULTS

Gut-brain signaling controls systemic cholesterol
Daily subcutaneous administration of ghrelin in wildtype mice for 1 week not only caused the expected increase in body fat 7 (3.3 ± 0.1 versus 1.9 ± 0.3 g, P < 0.001), but also significantly increased total plasma cholesterol levels in these mice relative to vehicleinfused con trol mice (132.0 ± 4.7 versus 116.5 ± 1.4 mg dl −1 , P < 0.05). Plasma triglyceride (101.1 ± 7.8 versus 82.6 ± 4.4 mg dl −1 , P = 0.058) and plasma glucose levels (97.6 ± 1.1 versus 96.2 ± 0.9 mg dl −1 ) remained unchanged. As most of ghrelin's effects on metabolism are believed to be mediated via its primary CNS target, the hypothalamic melano cortin system, we asked whether blockade or activation of such CNS circuitry would affect circulating cholesterol.
To determine whether the central melanocortin system could mediate the effects of ghrelin on cholesterol, we inhibited melano cortin signaling indirectly and directly by chronic intracerebroven tricular (icv) administration of ghrelin or the melanocortin receptor antagonist SHU9119. To prevent ghrelin/SHU9119induced hyper phagia (Supplementary Fig. 1 ) as a confounding factor, we pairfed rats, limiting them to the amount of calories consumed by the icv vehicle-infused control group (Supplementary Fig. 1 ). Chronic icv infusion of ghrelin or SHU9119 increased total plasma choles terol (Supplementary Fig. 2 ). This increase in cholesterol was a result of higher HDL cholesterol (HDLC; Fig. 1a) , implying that CNS melanocortin receptor activity regulates circulating HDLC 8 7 8 VOLUME 13 | NUMBER 7 | JULY 2010 nature neurOSCIenCe a r t I C l e S independently of food intake. Notably, icvadministered SHU9119 increased circulating HDLC to a greater extent than icv ghrelin (Fig. 1a) . Leptin and adiponectin levels also increased in response to CNS ghrelin or SHU9119 infusion, whereas several inflammatory markers remained unchanged (Supplementary Fig. 2 ). To determine whether HDLC levels can be regulated in both directions by sign aling changes in the CNS, we next administered the melanocortin receptor agonist MTII or the melanocortin antagonist SHU9119 directly into the lateral ventricle. Although chronic icv infusion of the melanocortin agonist MTII decreased plasma HDLC levels, SHU9119 potently increased HDLC (Fig. 1b) . Notably, changes in HDLC induced by the blockade of the central melanocortin system were observed under conditions in which no change in body mass occurred (Supplementary Fig. 1 ).
To determine whether the hungerinducing hormone ghrelin is the only gut hormone that controls cholesterol metabolism via the CNS, we evaluated the satiating hormone GLP1, which has recently been shown to oppose ghrelin in the hypothalamic melano cortin system 8 . Icv infusion of GLP1 in mice for 1 week decreased circulating cholesterol compared with ad libitum and pair-fed vehicleinfused control mice (Supplementary Fig. 2 ). These data indicate that circulating cholesterol levels can be both positively and negatively regulated in response to the action of peripheral gastrointestinal hormones. We concluded that a neuroendocrine circuit involving the gutbrain axis controls HDLC independently of changes in food intake or body weight. We then investigated whether CNS signaling-induced modulation of HDLC involves changes in the size of the HDL particles. Using ultracentrifugation, we purified HDL particles from pairfed rats infused icv with ghre lin or SHU9119. The migration in a nondenaturing gel of purified HDL particles was not substantially affected by the icv treatment of ghrelin or SHU9119 (Supplementary Fig. 3 ), similar to the fast protein liquid chromatography (FPLC) elution pattern that we found in pairfed rats. Thus, these findings indicate that the treatment did not change the size of the HDL particles. For additional verification of the lipoprotein separation by FPLC, we asked whether the increase in HDLC was associated with an increase in apolipoprotein (Apo) AI levels. Total plasma Apo AI levels were similar among groups (Supplementary Fig. 3 ), but immunoblots from FPLC fractions revealed that icvadministered SHU9119 increased both HDLC and Apo AI levels in HDL fractions (Fig. 1c) . Apo B measurements confirmed the absence of lowdensity lipoprotein (LDL) particles in these fractions (Fig. 1c) . This increase in HDLC and Apo AI levels induced by the blockade of the central melanocortin system occurred in spite of a considerable reduction in hepatic Apoa1 and Abca1 gene expression ( Supplementary Fig. 4) .
To determine whether modulation of CNS melanocortin 4 receptor (MC4R) signaling affects cholesterol fluxes in vivo, we asked whether blockade of the central melanocortin receptors changed the plasma clearance of injected radiolabeled HDLC. We intravenously injected HDL particles labeled with 3 Hcholesterol into rats that were simul taneously icv infused with SHU9119 for 4 d (implanted osmotic mini pumps). Icv SHU9119 infusion significantly decreased the plasma clearance of HDLC (P < 0.05; Fig. 1d ). These findings suggest that changes in circulating HDLC in response to altered CNS melano cortin signaling is a result of decreased HDLC reuptake rather than being a consequence of increased hepatic synthesis.
Because hypothalamic neuronal circuitries control hepatic glucose metabolism via the autonomic nervous system 9 , we hypothesized that the efferent vagus nerve may be a crucial pathway mediating the CNS modulation of plasma HDLC levels. We found that hepatic vagotomy did not affect the HDLC levels in icvadministered saline control pairfed rats, but abolished SHU9119induced increases of HDLC (Supplementary Fig. 5 ).
Lack of Ghrl/Ghsr or Mc4r directly affects plasma cholesterol To determine whether the endogenous ghrelin and melanocortin systems have a physiological role in the regulation of cholesterol, we quantified circulating cholesterol in mice lacking ghrelin (Ghrl −/− mice), ghrelin receptor (Ghsr −/− mice) or both (Ghrl −/− ; Ghsr −/− ), and in mice deficient for MC3R (Mc3r -/-) and MC4R (Mc4r -/-). Ghrl −/− and Ghsr −/− mice had modestly reduced circulating cholesterol (Fig. 2a) , whereas Ghrl −/− ; Ghsr −/− mice had significantly lower (P < 0.05) circulating cholesterol than wildtype controls. Lipoprotein profiles a r t I C l e S of these Ghrl −/− ; Ghsr −/− mice revealed that differences in plasma cholesterol were predominantly a consequence of decreased HDLC fractions in mice with deficient ghrelin signaling (Fig. 2b) .
Conversely, cholesterol levels were increased in mice deficient for MC4R, especially on a highfat diet (Fig. 2c,d ). Mice defi cient for MC3R developed obesity 10 , but did not exhibit a clear increase in circulating cholesterol 11 . MC4R knockout mice also had significantly higher cholesterol levels than fat mass-and sex matched C57BL/6 mice (P < 0.01) or lean wildtype mice (P < 0.001) (Fig. 2e,f) . These data confirm the physiological relevance of neuro endocrine cholesterol regulation by ghrelin and the melanocortin system independent of body fat and indicate that MC4R is a crucial hypothalamic receptor subtype for the neuroendocrine control of HDLC.
Neuroendocrine control of hepatic HDL-C re-uptake On the basis of our finding in rats with blocked CNS melanocortin receptors, which showed increased Apo AI in FPLC fractions con taining HDL particles in spite of reduced hepatic Apo AI synthesis, we reasoned that higher levels of HDLC in plasma may be primarily a result of decreased hepatic cholesterol reuptake. We assessed this hypothesis by analyzing mRNA expression of several components of hepatic cholesterol reuptake following direct (SHU9119) and indirect (ghrelin) inhibition of the central melanocortin system. Icv administration of ghrelin or SHU9119 under pairfed condi tions potently downregulated gene expression of one major hepatic receptor responsible for HDLC reuptake, the scavenger receptor class B type 1 Scarb 1 (Fig. 3a) . Components of separate pathways involved in the regulation of hepatic cholesterol uptake, such as the protein convertases Pcsk9 and Pcsk5, were not significantly changed (P > 0.05; Supplementary Fig. 4 ). Transcription factors that are known to control Scarb1 expression 12, 13 , such as farnesoid X recep tor (FXR, Nr1h4) and liver receptor homolog 1 (LRH1, Nr5a2), were downregulated in rat livers following icvadministered ghrelin or SHU9119 independent from food intake (Fig. 3b,c) . To assess physio logical importance, we used Ghsr −/− mice, as MC4R-deficient mice are morbidly obese and Ghsr −/− mice have normal body weight and food intake. Hepatic expression levels of Scarb1 (5.1 ± 1.0, P < 0.01), FXR (2.5 ± 0.2, P < 0.001) and LRH1 (2.6 ± 0.3, P < 0.001) were all increased in Ghsr −/− mice (fold relative to Mrpl32 expression), indicating that our pharmacological findings are physiologically rel evant. Icv infusion of GLP1, a satietyinducing gut hormone that has been reported to modulate hypothalamic melanocortin signaling 8 , induced a significant increase (P < 0.05) in the hepatic expression levels of Scarb1 (Fig. 3d) , with hepatic levels of Nr1h4 and Nr5a2 mRNA tending toward increased expression (Fig. 3e,f) , suggest ing that gutbrain interactions can regulate Scarb1 gene transcription in both directions. In summary, these data suggest a gutbrain control system, which regulates cholesterol metabolism in response to changes in gastro intestinal nutrient availabilities. We then asked whether direct and indirect inhibition of the central melanocortin system would, in addition to decreasing hepatic choles terol reuptake, stimulate the hepatic synthesis of cholesterol. We measured mRNA expres sion of several signaling components involved in hepatic cholesterol synthesis and uptake Figure 3 Gut hormones and melanocortin action in the CNS modulates hepatic HDL-C re-uptake pathways independent of food intake. (a-f) Changes in Scarb1 (a,d), Nr1h4 (FXR, b,e) and Nr2h5 (LRH-1, c,f) hepatic mRNA levels. Ghrelin (2.5 nmol d −1 ) or SHU9119 (24 nmol d −1 ) were icv infused for 7 d in pair-fed (pf) Wistar rats (mean ± s.e.m., n = 8, a-c). GLP-1 (2.5 nmol d −1 ) was icv infused for 48 h in C57BL/6 male mice (mean ± s.e.m., n = 6-8, d-f). *P < 0.05, **P < 0.01 and ***P < 0.001 versus saline (one-way ANOVA). Fig. 4) . However, the neuroendocrine control of hepatic cholesterol syn thesis and uptake pathways could also be a consequence of parallel changes in body weight or food intake. We therefore asked whether acute icv injec tions of ghrelin or SHU9119 would elicit rapid changes of hepatic choles terol synthesis pathways; that is, before body weight changes could occur. Significant increases (P < 0.05) in the gene expression of factors related with hepatic cholesterol synthesis and uptake (Hmgcr and Ldlr) were apparent 4 h after ghrelin and SHU9119 administration ( Supplementary  Fig. 4) . Under pairfeeding conditions, however, the effects of chronically changed neuroendocrine signaling on pathways involved in cholesterol synthesis were much less impressive (Fig. 4a-d and Supplementary   Fig. 4) . We therefore concluded that, although it may represent one contributing component, a CNS control of hepatic cholesterol synthesis pathways could not fully explain the powerful neuroendocrine control of circulating HDLC.
Increased HDL-C in rats prone to diet-induced obesity Several reports have indicated that obesity does not abolish cen tral sensitivity to melanocortin receptor agonists 14, 15 . Rodents with increased susceptibility to dietinduced obesity (dietinduced obese (DIO) sensitive) have an increased ratio of endogenous melanocortin antagonist to agonist ligands (agoutirelated protein/melanocyte stimulating hormone) and higher expression of MC4R. This results in decreased hypothalamic melanocortin signaling when compared with animals that are resistant to dietinduced obesity (DIO resist ant) 16 . We identified DIOsensitive (1,031 ± 35 g) and DIOresistant (650 ± 16 g) rats from a large pool of rats that were maintained on a highfat diet for 10 months (Fig. 5a) . As expected 16 , DIOsensitive rats exhibited enhanced orexigenic drive after food deprivation (Fig. 5b) . A detailed analysis of lipoprotein cholesterol distribution indicated that DIOsensitive rats had higher cholesterol in Apo B-containing lipoproteins than their DIOresistant counterparts or chowfed con trols (Fig. 5c,d ). This is not surprising considering the extreme obesity and the diet of these rats. Notably, DIOsensitive rats also exhibited increased HDLC and Apo AI levels (Fig. 5c,d ) and decreased hepatic Scarb1 protein levels ( Supplementary Fig. 6 ); Scarb1 gene expression tended to be reduced as well (Supplementary Fig. 6 ).
To determine whether decreasing CNS melanocortin receptor activ ity would enhance the high fat diet (HFD)induced accumulation of HDLC, we icvinfused SHU9119 into rats whose diet was switched from chow to HFD for the duration of the experimental period. Chronic icv infusion of SHU9119 more potently increased plasma a r t I C l e S cholesterol, HDLC and Apo AI levels in rats on the highfat diet than in rats infused with saline, whereas LDL cholesterol and Apo B levels remained unchanged (Fig. 5e,f and Supplementary Figs. 2  and 3) . This difference in cholesterol response to SHU9119 icv infu sion between DIOsensitive and DIOresistant occurred despite icv administered SHU9119 having similar effects on food intake and body weight (Supplementary Fig. 1 ) and was accompanied by decreased hepatic Scarb1 protein levels in icv SHU9119-treated rats independ ent of the diet (Supplementary Fig. 6 ). Again, these results suggest a decreased reverse cholesterol transport induced by blocked CNS melanocortin signaling. To further test CNS MC4R hypersensitivity on highfat diet 16 , we asked whether acute icv treatment with MTII at a dose that does not affect plasma cholesterol in rats on standard chow diet could rescue hypercholesterolemia in rats on a highfat diet. Acute icv injection of MTII significantly decreased (P < 0.05) plasma cholesterol in DIO rats on a highfat diet, but not on standard chow (Fig. 5g) . This finding confirms the metabolically relevant hyper sensitivity of the hypothalamic melanocortin system 16 and suggests that acute CNS signaling changes can potently decrease plasma cholesterol without changing body fat mass.
DISCUSSION
We found that circulating levels of HDLC can be modulated in the CNS. Specifically, we found that the hypothalamic melanocortin system and its only known circulating inhibitor, ghrelin, regulate plasma HDLC levels through vagally mediated modulation of hepatic path ways controlling cholesterol synthesis and reuptake. The satiating gut hormone GLP1, however, activates the CNS melanocortin system and opposes ghrelin's actions on hepatic cholesterol metabolism. Our results strongly suggest that the same CNS circuits that promote food intake and facilitate energy storage also have a specific role as a remote control system for hepatic cholesterol synthesis. Our data further indicate that, in addition to facilitating hepatic cholesterol synthesis, the central melanocortin system influences cholesterol transport by modulating HDL cholesterol levels.
Reduced CNS melanocortin receptor signaling reduced hepatic Scarb1 expression, suggesting that Scarb1 has an important mecha nistic role in the CNS control of plasma HDLC. Genetically modified mice lacking Scarb1 (refs. 17, 18) have high HDLC, indicating that Scarb1 is important for selective cholesterol uptake from HDL par ticles. Indeed, mice exhibiting a complete lack of Scarb1 expression exhibit accumulation of large HDL particles 17 . Others have reported that a mouse model with a mutated Scarb1 promoter that decreases its hepatic expression by 50% had a proportional reduction in HDLC removal from plasma 18 . Notably, when the cholesterol distribution in these mice was studied by FPLC, there was a slight increase of choles terol in fractions containing large HDL particles and an increase of more than 50% in cholesterol levels in the HDL region. Furthermore, these mice had higher Apo AI lipoprotein content than wildtype mice. These findings are consistent with our results, which does not exclude the possibility that multiple mechanisms involved in the con trol of lipoprotein cholesterol transport are modulated by the central melanocortin system. However, our data suggest that the decrease in hepatic Scarb1 levels could explain the increase in HDLC and Apo AI levels induced by the blockade of the central melanocortin system. Conversely, the activation of the melanocortin system decreases plasma cholesterol levels and increases hepatic Scarb1 expression. We found that this mechanism was indirectly used by afferent gastro intestinal hormones such as ghrelin or GLP1, which are known to have opposite effects on the central melanocortin system and food intake. In summary, neuroendocrine gutbrain pathways known to promote intake and storage of calories also appear to prevent the elimination of a metabolite that is essential for many anabolic proc esses, and vice versa.
We found that the gutbrain control of cholesterol metabolism is inde pendent of changes in food intake or body weight. In several shortterm experiments, cholesterol metabolism changes preceded body weight changes ( Fig. 5g and Supplementary Fig. 1 ). Cholesterol changes were observed in genetic and pharmacological experiments using lean rodent models or during normal food intake (Figs. 2a,b and 5b) . In chronic studies, cholesterol metabolism was changed, whereas body adiposity remained stable (Supplementary Fig. 1 ). It has been reported that insulin facilitates the translocation of Scarb1 to the mem brane in adipocytes 19 and hepatocytes 20 . Previous studies have found that this translocation of Scarb1 to the plasma membrane induced by insulin is mediated by phosphatidylinositol 3kinase activity, suggest ing that the Scarb1 cholesterol uptake could be impaired in situations of insulin resistance 20 . However, we found that neuroendocrine mod ulation of plasma cholesterol (Supplementary Fig. 2 ) was achieved in the absence of impaired glucose homeostasis (Supplementary Figs. 2  and 4) . Cholesteryl ester transfer protein (CETP) decreases the amount of cholesterol in HDL, facilitating the transfer of cholesteryl esters from HDL particles to more atherogenic triglyceridecontain ing lipoproteins 21 , and is increasingly active in obesity 22 . The absence of CETP in rodents indicates that it is not involved in the cholesterol regulation pathway that we examined, further supporting the idea that a gutbrain axis affects cholesterol metabolism by modulating hepatic synthesis and reuptake. Several studies have reported lower levels of the HDL receptor Scarb1 in obese mice lacking leptin signaling, such as ob/ob and db/db mice 23, 24 . Furthermore, studies 25, 26 have indicated that leptin may be a molecular regulator of HDL cholesterol. Leptin action promotes hepatic Apoa1 gene expression, decreases HDLC plasma levels and increases HDLC uptake from hepatocytes in ob/ob mice 25, 26 . From our data, we speculate that leptin may affect HDLC metabolism via its main target in the brain, the CNS melanocortin system 4 . An integrated neuroendocrine control of food intake, body weight and glucose homeostasis, as well as cholesterol metabolism and cardiovascular lipid exposure, would connect all of the hallmarks of the metabolic syndrome. Therapies promoting the increase of HDL levels have been proposed for the prevention of atherosclerosis in humans 27 . However, in rodent models lacking CETP, increased HDLC is frequently associated with the metabolic syndrome. Ob/ob mice, which have high HDLC levels, exhibit massive atherosclerosis on an Ldlr −/− background, which is more relevant for human atherosclero sis 28 . In addition, rodent models with high HDLC levels resulting from deficiency for Scarb1 are also prone to atherosclerosis 29, 30 . We speculate that modulation of neuroendocrine circuits may offer thera peutic opportunities to prevent cardiovascular disease.
A sterol regulatory element binding protein-regulated pathway con trols the de novo cholesterol synthesis 31 . When cholesterol is depleted in the liver, sterol regulatory element binding proteins increase choles terol biosynthesis and upregulate LDL receptor expression to increase lipoprotein uptake from the plasma 32 . We propose that, in parallel with these canonical control mechanisms, liver cholesterol metabolism and blood cholesterol levels also are under the immediate control of specific CNS circuits. Such a conclusion supports the idea that the CNS directs a number of critical aspects of peripheral metabolism 33 via the auto nomic nervous system and the classic endocrine axes 34 . Such processes under neuroendocrine control include food intake 35 , adaptive thermo genesis 36 and endocrine pancreas function 37 . More recent studies have integrated the CNS control of nonexercise activity thermogenesis 38 or hepatic glucose production 9 . Recent reports on CNS control of lipid a r t I C l e S metabolism suggested a potentially direct neuroendocrine control of triglyceride metabolism in liver 39 or adipose tissue 40 .
Our observations add a component to the existing model of neuro endocrine control of peripheral metabolism by showing for the first time, to the best of our knowledge, that circulating levels of cholesterol are under remote, but direct, control of specific neuroendocrine cir cuits in the CNS. Numerous synthetic agonists for CNS MC4Rs have been described and potent ghrelin receptor antagonists are currently emerging. Direct or indirect pharmacological modulation of hypo thalamic melanocortin tone may offer a potent way to treat hyper cholesterolemia and to simultaneously target all major components of the metabolic syndrome.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
